Management of Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Recommendations of a Multidisciplinary Panel of Experts from South America

<table class="algorithm-group"><tr><td><table class="algorithm" id="alg3"><tr><td>(i)</td><td> Second-generation antiandrogens are considered overall safe, provided that treatment is prescribed according to current indications</td></tr><tr><td>(ii)</td><td>Signs of cognitive decline should be proactively watched out for during treatment with second-generation antiandrogens</td></tr><tr><td>(iii)</td><td>The inclusion of specific questionnaires for monitoring cognitive function in M0CRPC patients treated with second-generation antiandrogens may be useful to enhance the safety of these therapies</td></tr></table></td></tr></table>

<div> Recommendations regarding adverse events in the treatment of patients with M0CRPC.</div>

Prostate Cancer

alg3

Box 3

Box 3: Management of Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Recommendations of a Multidisciplinary Panel of Experts from South America 

Box 3 | Management of Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Recommendations of a Multidisciplinary Panel of Experts from South America 